Algeta enters research collaboration to evaluate thorium conjugated with a novel tumor-targeting antibody from Genzyme
Algeta ASA announced that it has entered a research collaboration with Genzyme to evaluate the potential of its thorium platform.
Under the terms of the collaboration, Genzyme will provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially.
Thomas Ramdahl, Executive Vice President and Chief Technology Officer, said: "We are delighted to work with Genzyme on this important new approach to cancer treatment, which combines our cancer-killing payload thorium-227 with the novel antibody's own target specificity and tumor cell degradation properties. Algeta has previously demonstrated the promise of our alpha-emitter thorium-227 as a payload and we now look forward to applying our Thorium platform to this novel antibody."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.